Clinical Trials Directory

Trials / Active Not Recruiting

Active Not RecruitingNCT06950710

Mechanisms of Macrophage Polarization in HIRI in Patients With NAFLD

Mechanisms of Macrophage Polarization in Hepatic Ischemia-Reperfusion Injury in Patients With Non-Alcoholic Fatty Liver Disease

Status
Active Not Recruiting
Phase
Study type
Observational
Enrollment
300 (estimated)
Sponsor
Zhifeng Gao · Academic / Other
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

To better understand the occurrence of hepatic ischemia-reperfusion injury (IRI) in patients with non-alcoholic fatty liver disease (NAFLD) and the role of macrophage polarization in this process, this study will retrospectively collect clinical data from patients who underwent partial hepatectomy at Beijing Tsinghua Changgung Hospital between September 2021 and March 2025. Additionally, clinical information and liver blood samples from patients scheduled for partial hepatectomy from April 2025 onward will be prospectively collected. These samples will include normal liver tissue from the resected portion, as well as 5 mL of venous blood obtained before and after surgery. The investigators will compare the severity of hepatic IRI, the expression of macrophage polarization-related proteins, and macrophage polarization markers in blood samples between NAFLD patients and controls. The study aims to determine whether NAFLD patients experience more severe hepatic IRI and to elucidate the role and mechanisms of macrophage polarization in this context. The findings will provide a theoretical basis for understanding the molecular mechanisms underlying hepatic IRI in NAFLD patients, thereby identifying potential therapeutic targets to prevent IRI and improve prognosis in NAFLD patients undergoing partial hepatectomy.

Conditions

Interventions

TypeNameDescription
OTHERNAFLDThis study is an observational one with no intervention

Timeline

Start date
2025-04-01
Primary completion
2026-06-30
Completion
2026-06-30
First posted
2025-04-30
Last updated
2025-04-30

Locations

1 site across 1 country: China

Source: ClinicalTrials.gov record NCT06950710. Inclusion in this directory is not an endorsement.